3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Non-Small-Cell Lung
2
Tracheal Diseases
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Adenoid Cystic
1
Advanced or Metastatic Solid Tumors
1
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Combined Modality Therapy
×
1 year
×
Clear all
No trials found.